Status:
UNKNOWN
Synthetic CBD as a Therapy for COVID-19
Lead Sponsor:
Sheba Medical Center
Conditions:
Covid19
CBD
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compa...
Eligibility Criteria
Inclusion
- COVID 19 patients
- 18 Years and older
Exclusion
- Respiratory failure requiring mechanical ventilation
- Intensive care unit admission
- Neutrophile con. \< 1000 cells/mm3
- Lymphocyte con \< 500 cells/mm3
- Liver enzymes 5 times higher then the norm
- QT interval longer then 500 ms.
- Pregnancy
- Hemodialysis renal replacement therapy
- Active or prior psychotic event
Key Trial Info
Start Date :
January 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04686539
Start Date
January 20 2021
End Date
January 1 2022
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center, Tel Hashomer
Ramat Gan, Tel Aviv, Israel